Geetanjali Dang, MD
Cardiovascular Disease · Jacksonville, FLNPI 1760770291
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (46.4%), food and beverage and other — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Abbott at 35.5% of the total. 2025 is the largest year on record at $5,707, 5.3 times the $1,069 reported in 2019.
Across 172 payments — averaging $82.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Edwards Lifesciences$3K
- Butterfly Network, Inc.$2K
- Medtronic$1K
- Novartis$278
- Merck$276
- plus $2K from 20 others
What the payments were for
- Travel & lodging$6,58046%
- Food & beverage$5,20037%
- Education$70%
- Other$2,39917%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 40 | $5,029 |
| Edwards Lifesciences | 17 | $3,133 |
| Butterfly Network, Inc. | 1 | $2,399 |
| Medtronic(2 entities) | 14 | $1,320 |
| Novartis | 14 | $278 |
| Merck | 14 | $276 |
| Siemens Medical Solutions USA, Inc. | 4 | $268 |
| E.r. Squibb & Sons, L.L.C. | 12 | $236 |
| Pfizer | 11 | $231 |
| Boehringer Ingelheim | 7 | $171 |
| Kestra Medical Technology Services, Inc. | 6 | $138 |
| Amgen | 7 | $117 |
| Bracco Diagnostics Inc. | 1 | $79 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $68 |
| Johnson & Johnson | 3 | $64 |
| GE HealthCare | 1 | $59 |
| Baxter Healthcare | 3 | $54 |
| Boston Scientific | 2 | $52 |
| AstraZeneca | 3 | $51 |
| Esperion Therapeutics, Inc. | 2 | $39 |
| Philips North America LLC | 1 | $31 |
| W. L. Gore & Associates, Inc. | 1 | $23 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $19 |
| Vital Connect, Inc | 1 | $16 |
| Cleerly, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Butterfly iQ$2,399
- TRICLIP$1,450
- MitraClip$1,291
- PASCAL$1,193
- NAVITOR$1,172
- EVOQUE$947
- COBALT DR MRI SURESCAN$182
- Edwards SAPIEN 3 Transcatheter Heart Valve$109
How this compares
$14,186 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 233 | $205,160 |
| JardianceEmpagliflozin | 55 | $54,198 |
| EntrestoSacubitril/Valsartan | 38 | $52,182 |
| Repatha SureclickEvolocumab | 47 | $33,464 |
| XareltoRivaroxaban | 17 | $18,625 |
| Atorvastatin Calcium | 263 | $2,328 |
| Metoprolol Succinate | 181 | $1,872 |
| Losartan Potassium | 209 | $1,670 |
| Carvedilol | 259 | $1,661 |
| Rosuvastatin Calcium | 101 | $1,250 |
| Midodrine Hcl | 11 | $1,227 |
| Amlodipine Besylate | 201 | $1,202 |
| Ezetimibe | 60 | $818 |
| Nebivolol Hcl | 18 | $741 |
| Lisinopril | 82 | $597 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $231 | $205,160233 claims |
| Boehringer IngelheimJardiance | $171 | $54,19855 claims |
| NovartisEntresto | $278 | $52,18238 claims |
| Johnson & JohnsonXarelto | $64 | $18,62517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Jacksonville
- Alan MillerJacksonville$547K
- Samer GarasJacksonville$258K
- Jose Nativi-NicolauJacksonville$125K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.